Lancashire and South Cumbria
Formulary
Formulary
5 Infections
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
This chapter of the formulary is under development, please use local/national antimicrobial guidelines to support prescribing choices.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net
Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns. |
05-01-12 Quinolones
Quinolones may induce convulsions in patients with or without a history of convulsions; taking NSAIDs at the same time may also induce them.
Tendon damage (including rupture) has been reported rarely in patients receiving quinolones.
| Levofloxacin |
|
Formulary
|
Intravenous infusion 500mg/100mL If use is not in line with local antimicrobial guidance, then please contact microbiology for advice. |
|
| Levofloxacin |
|
Formulary
|
Tablets 250mg, 500mg If use is not in line with local antimicrobial guidance, then please contact microbiology for advice. |
|
Links
Blackpool Teaching Hospitals: Antimicrobial Formulary- British Association for Sexual Health and HIV
- Central Lancashire/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections
- East Lancashire Primary Care: Antimicrobial guide primary care
- East Lancashire Secondary Care: Antimicrobial guide secondary care
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store)
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google)
- MHRA Drug Safety Update Dec 2020: https://www.gov.uk/drug-safety-update/systemic-and-inhaled-fluoroquinolones-small-risk-of-heart-valve-regurgitation-consider-other-therapeutic-options-first-in-patients-at-risk
- MHRA Drug Safety Update Dec 2020: Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk
- MHRA Drug Safety Update Dec 2020: Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk
- MHRA Drug Safety Update Dec 2020: Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk
- MHRA Drug Safety Update Dec 2020: Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk
- MHRA Drug Safety Update Dec 2020: Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk
- MHRA Drug Safety Update Dec 2020: Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk
- MHRA Drug Safety Update Dec 2020: Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk
- MHRA Drug Safety Update Nov 18: Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients
- MHRA Drug Safety Update Nov 18: Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients
- MHRA Drug Safety Update Nov 18: Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients
- MHRA Drug Safety Update Nov 18: Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients
- MHRA Drug Safety Update Nov 18: Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients
- MHRA drug Safety Update Nov 18: Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients
- MHRA drug Safety Update Nov 18: Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients
- MHRA Drug Safety Update Nov 18: Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients
- MHRA Drug Safety Update: Moxifloxacin: increased risk of life-threatening liver reactions and other serious risks
- MHRA Drug Safety Update: Moxifloxacin: increased risk of life-threatening liver reactions and other serious risks
- MHRA: Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate
- MHRA: Fluoroquinolone antibiotics: suicidal thoughts and behaviour
- MHRA: Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients
- NICE CG165: Hepatitis B (chronic): diagnosis and management
- NICE NG110: Prostatitis (acute): antimicrobial prescribing
- NICE NG111: Pyelonephritis (acute): antimicrobial prescribing
- NICE NG114: Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing
- NICE NG117: Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing
- NICE NG120: Cough (acute): antimicrobial prescribing
- NICE NG125: Surgical site infections: prevention and treatment
- NICE NG138: Pneumonia (community-acquired): antimicrobial prescribing
- NICE NG139: Pneumonia (hospital-acquired): antimicrobial prescribing
- NICE NG141: Cellulitis and erysipelas: antimicrobial prescribing
- NICE NG152: Leg ulcer infection: antimicrobial prescribing
- NICE NG153: Impetigo: antimicrobial prescribing
- NICE NG182: Insect bites and stings: antimicrobial prescribing
- NICE NG184: Human and animal bites: antimicrobial prescribing
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG190: Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG198: Acne vulgaris: management
- NICE NG199: Clostridioides difficile infection: antimicrobial prescribing
- NICE NG240: Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
- NICE NG50: Cirrhosis in over 16s: assessment and management
- NICE NG51: Sepsis: recognition, diagnosis and early management
- NICE NG78: Cystic fibrosis: diagnosis and management
- NICE NG79: Sinusitis (acute): antimicrobial prescribing
- NICE NG84: Sore throat (acute): antimicrobial prescribing
- NICE NG91: Otitis media (acute): antimicrobial prescribing
- NICE NG95: Lyme disease
- UHMB Pharmacy Notification Dec 18 : Restriction of fluoroquinolone antibiotics due to disabling and potentially permanent side effects
- UHMB Pharmacy Notification Dec 18 : Restriction of fluoroquinolone antibiotics due to disabling and potentially permanent side effects
- UHMB Pharmacy Notification Dec 18 : Restriction of fluoroquinolone antibiotics due to disabling and potentially permanent side effects
- UHMB Pharmacy Notification Dec 18 : Restriction of fluoroquinolone antibiotics due to disabling and potentially permanent side effects
- UHMB Pharmacy Notification Dec 18: Restriction of fluoroquinolone antibiotics due to disabling and potentially permanent side effects
- UHMB Pharmacy Notification Dec 18: Restriction of fluoroquinolone antibiotics due to disabling and potentially permanent side effects
- UHMB Pharmacy Notification Dec 18: Restriction of fluoroquinolone antibiotics due to disabling and potentially permanent side effects
- University Hospitals of Morecambe Bay: Antimicrobial guide secondary care
- West Lancashire Primary Care: Pan Mersey antimicrobial guide
- WHO: AWaRe classification of antibiotics for evaluation and monitoring of use, 2023